Shares of Replimune Group are rising Monday after the clinical stage biotechnology company shared an important regulatory ...
Replimune stock doubled to $9.00 after FDA accepted its resubmitted application for melanoma drug RP1, with decision expected April 2026.
Speed up your language learning with AI. This guide provides 4 expert tips for using ChatGPT to master conversation, build ...
Replit is a great AI coding platform, but it's not the only option. Check out the prices, features, and code-generating ...
Replit expects to hit $1 billion in revenue next year as AI coding products replace old tools.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback